We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

The Assay Guidance Manual: A Guide for In Vitro and In Vivo Assays in Early Drug Discovery

  • Print
  • Email


The Assay Guidance Manual is a guide for scientists working in the early stages of drug development. The manual includes guidelines for selection, development and optimization of various in vitro and in vivo assays used for drug development. In this article, we highlight three chapters within the Assay Guidance Manual about cell viability assays, Short Tandem Repeat profiling analysis and cell-based assays for the detection of protein:protein interactions. Johanna Lee and Mariel Mohns Promega Corporation Publication Date: December 2018; tpub_191

In the early stages of drug development, proper use of in vitro and in vivo assays is critical for drug evaluation. But where do you begin? Which assays should you use? How do you analyze and validate results?

To help answer these questions, the NIH Chemical Genomics Center (NCGC) published an eBook called the Assay Guidance Manual (AGM). This eBook began as an internal guide within a pharmaceutical company, but now contains more than 40 chapters written by drug discovery scientists from academic, government and industrial research laboratories. The AGM eBook includes guidelines for selection, development and optimization of various in vitro and in vivo assays and how to adapt these assays for high-throughput screening. It also provides information on commercial products, potential assay interferences and statistical validation of assay performance.

Promega scientists contributed three chapters in the AGM; one on cell viability assays, another on authentication of human cell-lines using Short Tandem Repeat (STR) profiling analysis, and a third on cell-based assays for the detection of protein:protein interactions. We highlight these three chapters in this article.


Cell Viability Assays


Which common methods are used to measure cell viability?

One of the most common methods to detect cell viability in high-throughput workflows is by measuring ATP, which is only synthesized in viable cells. ATP can be measured using a bioluminescent assay with reagents containing stabilized luciferase and luciferin substrate. In the presence of ATP from viable cells, luciferase uses luciferin to generate luminescence, which is detected with a luminometer. The resulting luminescent signal is proportional to the number of viable cells. This method is great for high-throughput applications due to its superior sensitivity in higher density microwell plates. 

Many older cell viability assays require incubation of a reagent with viable cells to convert a substrate to a colored or fluorescent product that can be detected with a plate reader with absorbance or fluorescence capability. The resulting signal is proportional to the number of viable cells, because dead cells lose the ability to convert substrate to product. This is the basis for many of the commonly used cell viability assays, including tetrazolium reduction (such as MTT or MTS), resazurin reduction and live-cell protease activity assays. These assays are less sensitive than bioluminescent methods and are used in lower throughput applications.


How can cell viability be monitored in real-time?

A real-time cell viability assay was developed by Promega (see figure below). In this assay, an engineered luciferase and a prosubstrate (which is not a substrate of luciferase) are added directly to the culture medium. The prosubstrate can penetrate cell membranes and enter cells. However, only viable cells with active metabolism can reduce the prosubstrate into a substrate for luciferase. The substrate then exits the cell where it is used by luciferase in the detection reagent to generate a luminescent signal. The same wells can be measured repeatedly for 3 days. The main advantages of this method are that it allows simple kinetic monitoring to determine dose response using fewer plates and cells. Also, because the method does not require cell lysis, the same cells can be used in additional cell-based assays or downstream applications.

Promega product: RealTime-Glo™ MT Cell Viability Assay (Cat.# G9711)

RealTime-Glo™ MT Cell Viability Assay Overview.


How do ATP cell viability assays work?

ATP can be used to detect cell viability since only viable cells can synthesize ATP. ATP can be measured using a bioluminescent assay with reagents containing detergent, stabilized luciferase and luciferin substrate. The detergent lyses viable cells, releasing ATP into the medium. In the presence of ATP, luciferase uses luciferin to generate luminescence, which can be detected within 10 minutes using a luminometer (see figure below). The ATP assay is faster than other methods since it does not require incubation to convert a substrate into a colored product. The assay has excellent sensitivity and broad linearity, making it highly compatible with high-throughput assays. It is also less prone to artifacts than other methods.

Promega products: CellTiter-Glo® Luminescent Cell Viability Assay (Cat.# G7570), CellTiter-Glo® 2.0 Assay (Cat.# G9241)



How does the protease viability marker assay work?

Some protease activities disappear rapidly after cell death, so they can be a useful marker of viable cells. Live-cell protease activity can be measured using a cell-permeable fluorogenic protease substrate (GF-AFC). The substrate enters live cells where it is cleaved by live-cell protease to generate a fluorescent signal proportional to the number of viable cells (see figure below). The incubation time for this method is 0.5–1 hour, which is shorter than tetrazolium assays (1–4 hours). Because this method does not lyse cells, it allows for multiplexing with many other assays in the same sample wells, including bioluminescent cell-based assays.

Promega product: CellTiter-Fluor™ Cell Viability Assay (Cat.# G6080)

CellTiter-Fluor Cell Viability Assay chemistry.

How do resazurin reduction cell viability assays work?

Resazurin is a cell-permeable redox indicator that is dark blue in color with little intrinsic fluorescence. Only viable cells with active metabolism can reduce resazurin into resorufin, which is pink and fluorescent. After 1–4 hours of incubation, the signal is quantified using a microplate spectrophotometer or fluorometer. This method is relatively inexpensive and more sensitive than tetrazolium assays. However, fluorescence from compounds being tested may interfere with resorufin readings.

Promega product: CellTiter-Blue® Cell Viability Assay (Cat.# G8080)


How do tetrazolium reduction cell viability assays work?

Tetrazolium compounds used to detect viable cells fall in two basic categories:

  1. Positively charged compounds (MTT) that readily penetrate viable cells: Viable cells with active metabolism are able to convert MTT into a purple-colored formazan product. Thus, color formation can be a useful marker of viable cells. However, the incubation time for this method is long (usually 4 hours). Also, the formazan product is insoluble, so a solubilizing reagent must be added prior to recording absorbance readings.
  2. Negatively charged compounds (MTS, XTT, WST-1) that do not penetrate cells: These compounds must be combined with intermediate electron coupling reagents which can enter cells, be reduced and then exit the cell to convert tetrazolium to the soluble formazan product. The incubation time for this method is 1–4 hours. There is no need to add a solubilizing reagent since the resulting formazan is soluble, making it more convenient.

A disadvantage of all tetrazolium reduction assays is that they depend on the accumulation of colored or fluorescent products over time. Since the signal gradually increases over time, a decrease in viable cells during this long incubation cannot be detected.

Promega products: CellTiter 96® Non-Radioactive Cell Proliferation Assay (Cat.# G4000), CellTiter 96® AQueous One solution Cell Proliferation (Cat. #G3582)

Download the Assay Guidance Manual to learn more about these cell viability assays.


Authentication of Human Cell-Lines by STR Profiling Analysis


Why is it important to authenticate human cell-lines?

Cell-line misidentification and contamination has become a serious problem in biomedical research. Studies have shown that cross-contamination between cell-lines occurs at frequencies from 16–35%. Confirming the exact identity of a cell-line is important for interpreting experimental results, as data collected from contaminated cell-lines could lead to false conclusions and irreproducible results. Therefore, it is crucial to authenticate all cell-lines prior to their use.


What is STR analysis?

STR stands for “Short Tandem Repeat”, which are stretches of DNA containing core sequences of 1–6 bp that are tandemly repeated up to hundreds of times scattered throughout the genome. The number of repeats at each STR loci is highly variable between different individuals. By amplifying and analyzing the unique number of repeats in various STR loci, it is possible to trace the origin of cells and tissues to a single donor.


What are the advantages of STR analysis?

STR analysis is a universally accepted method for human cell-line authentication. This method is robust in its ability to identify unique human cell-lines. It is accessible and affordable through core facilities or service providers.


How is STR analysis done?

Many academic core facilities or commercial providers offer STR analysis services. STR analysis is easily performed using the PowerPlex® 18D System (Cat.# DC1802), which allows four-color fluorescent detection of eighteen STR loci, all co-amplified simultaneously in a single tube. The system is optimized for analysis of common database samples, such as direct amplification from unwashed sample collection card punches. The general process is described below:

  1. Spot cell suspension directly onto a sample collection card.
  2. Punch a disk in the center of the sample spot and place it in the well of a reaction plate.
  3. Add the appropriate amount of PowerPlex® 18D 5X Master Mix and 5X Primer Pair Mix.
  4. Place plate in the thermal cycler and start amplification.

Download the Assay Guidance Manual to learn more about the STR analysis protocol, how to interpret STR data and other troubleshooting tips.


BRET-Based Assays to Detect Protein:Protein Interactions in Live Cells


Why are protein:protein interactions important?

Protein:protein interactions (PPI) drive the dynamic processes in living cells. These protein targets are difficult to monitor due to the variety of amino acid lengths, binding affinities and complexity. Sensitive assays that can detect PPI in the cell are needed for high-throughput screening of compounds that may induce or inhibit these complex interactions. To gather the most accurate data, your PPI assay should be designed to reflect activity within the context of the cellular environment. Therefore, consider the cell type, transfection method, instrumentation readout and assay conditions when deciding which PPI assay will work best for your experimental needs.


What is the difference between FRET and BRET assays?

In a Förster resonance energy transfer (FRET) assay, fluorescent energy from a donor protein is transferred to an acceptor protein. When the PPI complex is formed, this energy transfer emits light detectable by flow cytometry or with a plate reader.

The bioluminescence resonance energy transfer (BRET) assay is also a proximity-based assay where energy is transferred from a luciferase donor with a fluorescent protein as the acceptor. When using optimized donor and acceptor proteins, this method has a better signal-to-background ratio and dynamic range.

Energy Transfer from NanoLuc to HaloTag NanoBRET Ligand


How does the NanoBRET™ assay work?

NanoBRET™ technology uses a NanoLuc® fusion protein as the bioluminescent donor and a fluorescently labeled HaloTag® fusion protein as the acceptor. The bright, blue-shifted donor signal and red-shifted acceptor create optimal spectral overlap, increased signal and lower background compared to conventional BRET assays.

NanoBRET™ can be performed in any cell line that can be transfected, with some optimization. Use phenol red-free medium to avoid interference with the acceptor signal. Proteins of interest can be tagged with either NanoLuc® luciferase or HaloTag® protein on either the N or C terminus, resulting in up to eigh possible constructs and eight possible combinations. Full-length proteins or protein domains can be used. The optimal ratio of donor and acceptor expression levels should be determined to reduce background and enhance the dynamic range.

To accurately perform NanoBRET™ PPI Assays, you will need an instrument that can sequentially measure dual-filtered luminescence values that is equipped with appropriate filters, such as the GloMax® Discover System (Cat.# GM3000). The donor emission occurs at 460nm, and the acceptor emission occurs at 618nm. For data analysis, the BRET ratio is calculated by dividing the acceptor signal by the donor signal. The raw BRET units can then be converted to milliBRET units by multiplying the value by 1,000.

Donor and Acceptor Signal Wavelengths for NanoBRET

Promega products: NanoBRET™ NanoGlo® Detection System (Cat.# N1661), NanoBRET™ PPI Starter Systems (Cat.# N1821)

Download the Assay Guidance Manual for more information on cell-based PPI assays.


How to Cite This Article

Lee, J. and Mohns, M. The Assay Guidance Manual. [Internet] December 2018; tpub_191. [cited: year, month, date]. Available from: http://www.promega.com/resources/pubhub/tpub_191-the-assay-guidance-manual/

Lee, J. and Mohns, M. The Assay Guidance Manual. Promega Corporation Web site. http://www.promega.com/resources/pubhub/tpub_191-the-assay-guidance-manual/ Updated December 2018; tpub_191. Accessed Month Day, Year.

CellTiter-Glo, CellTiter-Blue, CellTiter 96, GloMax, NanoLuc and PowerPlex are registered trademarks of Promega Corporation. CellTiter-Fluor, NanoBRET and RealTime-Glo are trademarks of Promega Corporation.